Edgewise Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Edgewise Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boulder
- Headquarters state / province
- Colorado
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- EWTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001710072
- EIN
- 82-1725586
Board of directors
-
Alan J. Russell · Director · Chief Scientific OfficerSince 2023
-
Arlene Morris · DirectorSince 2024
-
Badreddin Edris · DirectorSince 2023
-
Christopher Nathan Martin · DirectorSince 2025
-
Jonathan C. Fox · DirectorSince 2023
-
Jonathan D. Root · DirectorSince 2023
-
Kevin Koch · Director · President and CEOSince 2023
-
Laura Brege · DirectorSince 2023
-
Peter A. Thompson · DirectorSince 2023
Chief executives
Kevin Koch
· President and CEO
Dates unknown
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
65.0%
-
70.3%
-
95.8%
Board connections
5 of this board's directors also sit on 13 other boards.
- via Laura Brege
- via Peter A. Thompson
- via Christopher Nathan Martin
- via Jonathan D. Root
- via Arlene Morris
- via Peter A. Thompson
- via Laura Brege
- via Jonathan D. Root
- via Christopher Nathan Martin
- via Laura Brege
- via Arlene Morris
- via Peter A. Thompson
- via Arlene Morris
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $199,448
- 1 purchase by 1 insider
- Sold, last 12 months
- $19,502,266
- 33 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 13, 2026 | Donovan Joanne M. Officer (CMO) | Open-market sale | −2,919 | $43.41 | $126,704 |
| Aug 12, 2026 | Derakhshan Behrad Officer (Chief Business Officer) | Option exercise | +5,781 | — | — |
| Aug 12, 2026 | Donovan Joanne M. Officer (CMO) | Option exercise | +5,781 | — | — |
| Aug 12, 2026 | Kevin Koch Director, Officer (President and CEO) | Option exercise | +17,969 | — | — |
| Aug 12, 2026 | MOORE JOHN R Officer (General Counsel) | Option exercise | +5,781 | — | — |
| Aug 12, 2026 | Alan J. Russell Director, Officer (Chief Scientific Officer) | Option exercise | +5,781 | — | — |
| Aug 12, 2026 | Derakhshan Behrad Officer (Chief Business Officer) | Option exercise | +7,500 | — | — |
| Aug 12, 2026 | Donovan Joanne M. Officer (CMO) | Option exercise | +7,031 | — | — |
| Aug 12, 2026 | Kevin Koch Director, Officer (President and CEO) | Option exercise | +21,875 | — | — |
| Aug 12, 2026 | MOORE JOHN R Officer (General Counsel) | Option exercise | +6,718 | — | — |
| Aug 12, 2026 | Alan J. Russell Director, Officer (Chief Scientific Officer) | Option exercise | +7,031 | — | — |
| Aug 12, 2026 | Derakhshan Behrad Officer (Chief Business Officer) | Open-market sale | −2,171 | $43.79 | $95,075 |
| Aug 12, 2026 | Donovan Joanne M. Officer (CMO) | Open-market sale | −2,839 | $43.78 | $124,303 |
| Aug 12, 2026 | Kevin Koch Director, Officer (President and CEO) | Open-market sale | −8,782 | $43.64 | $383,254 |
| Aug 12, 2026 | MOORE JOHN R Officer (General Counsel) | Open-market sale | −2,439 | $43.81 | $106,848 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.